Drs. Marjan Farid and Nicole Fram discuss the key efficacy, safety, and comfort considerations when using these new pharmaceutical presbyopia treatments. They also describe the patients that will be the best candidates for pharmaceutical presbyopia treatments.
This activity is supported by an unrestricted educational grant from Johnson & Johnson Vision, and Orasis Pharmaceuticals
Upon completion of this activity, the participant should be able to:
There is no credit associated with this podcast.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Marjan Farid, MD
Director of Cornea, Cataract, and Refractive Surgery
Vice Chair of Ophthalmic Faculty
Clinical Professor of Ophthalmology
Gavin Herbert Eye Institute
University of California, Irvine
Nicole Fram, MD
Managing Partner at Advanced Vision Care in Los Angeles, CA
Clinical Instructor of Ophthalmology
Stein Eye Institute
University of California,Los Angeles
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Marjan Farid, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, BioTissue, Carl Zeiss Meditec, CorneaGen, Dompé, Eyepoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis.
Nicole Fram, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon Vision, Allergan, CorneaGen, Johnson & Johnson Vision, and Ocular Therapeutics. Grant/Research Support: Alcon Vision, and Allergan. Speaker’s List: Alcon Vision, BVI, CorneaGen, Dompé, MST, and Ocular Therapeutix. Stock/Shareholder: CorneaGen, and Ocular Science.
The Evolve and The Fundingsland Group staff and planners have no financial relationships with commercial interests.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, The Fundingsland Group, Johnson & Johnson Vision, and Orasis Pharmaceuticals.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
1.00 credit
Deepak Sambhara, MD
